dog on the beach

Invetx Completes Development of Canine and Feline Half-Life Extension Technology Platform that Significantly Extends Duration of Monoclonal Antibody Treatment Effect

July 25, 2023

Boston, MA- July 25, 2023 – Invetx, a pioneer in protein-based therapeutics for animal health, announced that it has recently completed development of its species-specific, half-life extension technology for dogs and cats which leads to superior extended duration of activity for the company’s veterinary monoclonal antibodies.

Invetx Appoints Dr. Marcus Remmers, Novo Holdings Partner and Animal Health Industry Leader, to Board of Directors

June 26, 2023

Boston, MA – June 26, 2023- Invetx, a pioneer in protein-based therapeutics for animal health, today announced the appointment of Dr. Marcus Remmers to its board of directors.

Invetx Announces Oversubscribed Series B Financing of $60.5 Million to Advance Portfolio of Best-in-Class Veterinary Biotherapeutics

May 10, 2022

Company positioned to bring portfolio of novel antibody product candidates through development to market approval Round includes new investors F-Prime Capital, Novo Holdings, GV and

Twist Bioscience Expands Partnership with Invetx to Include Discovery of Best-in-Class Antibodies to Treat Multiple Diseases in Cats and Dogs

November 18, 2021

SOUTH SAN FRANCISCO and BOSTON, Mass. – November 18, 2021 – Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering

Boehringer Ingelheim and Invetx Announce Strategic Collaboration to Advance Monoclonal Antibody Biotherapeutics in Animal Health

September 27, 2021

Collaboration Focused on Discovery, Development and Commercialization of  Novel Veterinary Medicines Ingelheim, Germany and Boston, MA- September 27, 2021- Boehringer Ingelheim, a global leader in

Invetx Announces Initiation of First Clinical Study in Dogs with IVX-01, its Novel Monoclonal Antibody Featuring Half-Life Extension

September 20, 2021

Company Appoints Dr. Robert Zolynas as Vice President, Clinical Development & Regulatory Affairs Boston, MA- September 20, 2021- Invetx, a pioneer in protein-based therapeutics for

Invetx Announces Completion of $25.5 Million Series A Financing and Key Appointments to Executive Team

September 30, 2020

New Investors Include Casdin Capital and Tekla Capital   Antibody Development Experts Bill Brondyk, PhD, Named Chief Scientific Officer and Colin Giles, PhD, Chief Development

Invetx Announces Industry-Leading Antibody Discovery Platform to Develop Portfolio of Novel Therapeutics for Animal Health

July 16, 2020

Platform Leverages Best-in-Class Technologies from AbCellera, Twist Bioscience and WuXi Biologics BOSTON, Mass. – July 16, 2020 – Invetx, a pioneer in protein-based therapeutics for

Twist Bioscience Partners with Invetx to Deliver Best-in-Class Antibody Therapeutics for Dogs and Cats

July 16, 2020

SOUTH SAN FRANCISCO and BOSTON, Mass. – July 16, 2020 – Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering

Invetx